Dr. Yang Pan leads clinical oncology biomarker development and translational efforts at Gilead Sciences. The focus of her research includes applying biomarkers (pharmacodynamic, predictive, prognostic and safety biomarkers) in all phases of clinical trials. Using conventional and innovative biomarker platforms from both tumor biopsies and noninvasive samples, the aims of Dr. Pan’s team are to inform dosing, understand mechanism of action and resistance in targeted patient populations. Prior to Gilead Dr. Pan was a Director of Medical Sciences at Amgen. Dr. Pan received her Ph.D. in Biochemistry from the University of California, San Diego and MBA from University of Washington Business School.
Track Chair: Cindy Perettie, Roche